← Leaderboards
Hiroaki Wakimoto
Massachusetts General Hospital
$2,299,893
Attributed
$4,136,233
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $750K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,136,233 · 4
By mechanism
R01$3,191,954 · 2
R21$944,279 · 2
Top collaborators
- Daniel P. Cahill7 shared
- Giulia Fulci2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- E. Antonio Chiocca$34,514,665
- Khalid A Shah$15,720,802
- Simon N Powell$16,981,652
- Christian T Farrar$7,804,648
- Daniel P. Cahill$3,140,317
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorCellsIn VivoGliomaPathway InteractionsMolecularCancer CellMediatingPhenotypeCytotoxicityConsumptionInnovationCombinatorialHematologyInvestigationGenesDependenceAdultEtiologyIsocitrate DehydrogenaseClinical TranslationDoseGenetic
Grant awards (11)
Analyzing DNA replication and damage vulnerability in IDH mutant glioma$401,140
R01 · FY2025 · CA
Analyzing DNA replication and damage vulnerability in IDH mutant glioma$396,982
R01 · FY2024 · CA
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$470,540
R01 · FY2022 · CA
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$480,143
R01 · FY2021 · CA
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$480,143
R01 · FY2020 · CA
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$465,738
R01 · FY2019 · CA
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$497,268
R01 · FY2018 · CA
Novel oncolytic virotherapy for brain tumors$252,708
R21 · FY2018 · NS · contact PI
Novel oncolytic virotherapy for brain tumors$210,845
R21 · FY2017 · NS · contact PI
Profiling and targeting micro-RNA expression during oncolytic virotherapy$215,226
R21 · FY2010 · NS · contact PI
Profiling and targeting micro-RNA expression during oncolytic virotherapy$265,500
R21 · FY2009 · NS · contact PI